S. boulardii Probiotics: A Central-Line Safety Check

Before adding a probiotic during treatment for a serious illness, show the treating team the ingredient label. Probiotics contain live microorganisms, including some yeasts.¹ The name Saccharomyces boulardii, often shortened to S. boulardii, deserves a specific conversation if you have a central venous catheter or weakened immunity.

What the hospital study found

Researchers reviewed Saccharomyces culture findings at five Finnish university hospitals during 2009–2018. They identified 46 people with fungemia, meaning fungi in the bloodstream.²

20 of those 46 people, at least 43%, had documented S. boulardii use on the culture date or in the preceding seven days. Ten patients’ records were unavailable and they were classified as nonusers.²

That does not mean 43% of probiotic users developed a bloodstream infection. The researchers started with infection cases; they did not establish an absolute infection rate among all users.²

The study was retrospective and lacked microbiological strain-matching evidence to confirm that the probiotic caused each infection. Its authors nevertheless did not recommend S. boulardii for people with indwelling catheters, impaired immunity or critical illness, and advised caution when intestinal integrity might be compromised.²

The concern applies to the patient, not just the bottle

The NIH Office of Dietary Supplements¹ describes side effects as usually minor in healthy people, while noting serious infections linked to probiotic use, mostly in people who were severely ill or immunocompromised. Reports involving Saccharomyces have included people in intensive care, receiving tube or intravenous feeding, or with central venous catheters.¹

An example of product-specific restrictions comes from Singapore’s Bioflor 250 mg sachet information, updated 9 October 2026. It lists central venous catheters and immunocompromised patients among its contraindications, including people hospitalized because of serious illness or altered immunity.³

That is Singapore information for a named medicine. Ask the pharmacist to check the instructions for your own product and country, alongside the clinical team’s advice.

Bring the organism name to the decision

If you already take a supplement, include it when the hospital, infusion service or specialist checks your medicines. Keep the bottle or photograph its complete label so the team can identify the organism and any strain designation.

Ask:

• “Does this contain S. boulardii, and is it suitable with my line and current treatment?”
• “What specific problem are we trying to prevent or treat?”
• “Is there evidence of benefit for this product in someone with my condition?”
• “If you advise against it, what should we do about the symptom that led me to buy it?”

The NIH fact sheet emphasizes that the strain and purpose matter when weighing evidence.¹ Do not substitute another probiotic on the assumption that a different organism has already passed that assessment.

In Bloated by Dinner, “Answer Two: Buy Something That Debloats” examines why findings for one probiotic do not automatically apply to the next bottle. For someone with a central line or serious illness, add suitability to that discussion before making a purchase or taking another dose.